Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia

American Journal of Surgical Pathology

Volumn 31, Issue 11, 2007, Pages 1733-1741

  Srivastava, Amitabh ^a   Odze, Robert D ^a   Lauwers, Gregory Y ^b   Redston, Mark ^a   Antonioli, Donald A ^c   Glickman, Jonathan N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Barrett esophagus; Interobserver variability; Intestinal metaplasia

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CARDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPT CELL; DIAGNOSTIC ACCURACY; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE CRYPT; INTESTINE METAPLASIA; KAPPA STATISTICS; LOWER ESOPHAGUS SPHINCTER; MALE; PARAMETER; REPRODUCIBILITY; SQUAMOUS EPITHELIUM;

ATROPHY; BARRETT ESOPHAGUS; BIOPSY; CARDIA; DIAGNOSIS, DIFFERENTIAL; ESOPHAGOGASTRIC JUNCTION; FEMALE; GASTRITIS; HUMANS; MALE; METAPLASIA; MIDDLE AGED; MUCOUS MEMBRANE; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 37349039637     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318078ce91     Document Type: Article

References (53)

1. Balaji NS, DeMeester SR, Wickramasinghe KS, et al. Etiology of intestinal metaplasia at the gastroesophageal junction. Surg Endosc. 2003;17:43-48.
2. Boyce HW. Barrett esophagus: endoscopic findings and what to biopsy. J Clin Gastroenterol. 2003;36:S6-S18; discussion S26-S28.
3. Chang Y, Gong J, Liu B, et al. Gene expression profiling in Barrett's esophagus and cardia intestinal metaplasia: a comparative analysis using cDNA microarray. World J Gastroenterol. 2004;10:3194-3196.
4. Chen YY, Wang HH, Antonioli DA, et al. Significance of acidmucin-positive nongoblet columnar cells in the distal esophagus and gastroesophageal junction. Hum Pathol. 1999;30:1488-1495.
5. Chu PG, Jiang Z, Weiss LM. Hepatocyte antigen as a marker of intestinal metaplasia. Am J Surg Pathol. 2003;27:952-959.
6. Couvelard A, Cauvin JM, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut. 2001;49:761-766.
7. Csendes A, Smok G, Quiroz J, et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol. 2002;97:554-560.
8. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol. 2002;97:2514-2523.
9. El-Serag HB, Sonnenberg A, Jamal MM, et al. Characteristics of intestinal metaplasia in the gastric cardia. Am J Gastroenterol. 1999;94:622-627.
10. El-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol. 2001;96:1378-1382.
11. el-Zimaity HM, Verghese VJ, Ramchatesingh J, et al. The gastric cardia in gastro-oesophageal disease. J Clin Pathol. 2000;53:619-625.
12. Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. Histopathology. 2003;43:127-134.
13. Glickman JN, Chen YY, Wang HH, et al. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol. 2001;25:569-578.
14. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol. 2001;25:87-94.
15. Glickman JN, Shahsafaei A, Odze RD. Mucin core peptide expression can help differentiate Barrett's esophagus from intestinal metaplasia of the stomach. Am J Surg Pathol. 2003;27:1357-1365.
16. Glickman JN, Ormsby AH, Gramlich TL, et al. Interinstitutional variability and effect of tissue fixative on the interpretation of a Barrett cytokeratin 7/20 immunoreactivity pattern in Barrett esophagus. Hum Pathol. 2005;36:58-65.
17. Goldblum JR. The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol. 2002;6:67-73.
18. Goldblum JR, Vicari JJ, Falk GW, et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology. 1998;114:633-639.
19. Goldblum JR, Richter JE, Vaezi M, et al. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol. 2002;97:302-311.
20. Goldstein NS, Karim R. Gastric cardia inflammation and intestinal metaplasia: associations with reflux esophagitis and Helicobacter pylori. Mod Pathol. 1999;12:1017-1024.
21. Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol. 2004;17:1282-1288.
22. Gulmann C, Shaqaqi OA, Grace A, et al. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus. Appl Immunohistochem Mol Morphol. 2004;12:142-147.
23. Gunther T, Hackelsberger A, Malfertheiner P, et al. Is typing of metaplasia at the squamocolumnar junction revealing its aetiology? Virchows Arch. 2000;436:6-11.
24. Kamberoglou DK, Savva SC, Kalapothakos PN, et al. Prevalence and risk factors associated with specialized intestinal metaplasia at the esophagogastric junction. Hepatogastroenterology. 2002;49:995-998.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
26. Lee RG. Mucins in Barrett's esophagus: a histochemical study. Am J Clin Pathol. 1984;81:500-503.
27. Malfertheiner P, Peitz U. The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut. 2005;54(suppl 1):i13-i20.
28. Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol. 2002;15:611-616.
29. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368-378.
30. Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol. 2004;57:1063-1068.
31. Morales TG, Sampliner RE, Bhattacharyya A. Intestinal metaplasia of the gastric cardia. Am J Gastroenterol. 1997;92:414-418.
32. Odze R. Cytokeratin 7/20 immunostaining: Barrett's oesophagus or gastric intestinal metaplasia? Lancet. 2002;359:1711-1713.
33. Odze RD. Unraveling the mystery of the gastroesophageal junction: a pathologist's perspective. Am J Gastroenterol. 2005;100:1853-1867.
34. Ormsby AH, Goldblum JR, Rice TW, et al. Sensitivity and specificity of histological features in diagnosis of Barrett's esophagus on routine endoscopic biopsy specimens. Am J Clin Pathol. 1999;112:A533.
35. Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol. 1999;30:288-294.
36. Ormsby AH, Kilgore SP, Goldblum JR, et al. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus. Mod Pathol. 2000;13:614-620.
37. Phillips RW, Frierson HF Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol. 2003;27:1442-1447.
38. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:1028-1032.
39. Sarbia M, Donner A, Franke C, et al. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry. Hum Pathol. 2004;35:371-376.
40. Sharma P. Recent advances in Barrett's esophagus: short-segment Barrett's esophagus and cardia intestinal metaplasia. Semin Gastrointest Dis. 1999;10:93-102.
41. Sharma P, Sampliner RE. Short segment Barrett's esophagus and intestinal metaplasia of the cardia - it's not all symantics!!! Am J Gastroenterol. 1998;93:2303-2304.
42. Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in shortsegment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol. 1997;92:2012-2016.
43. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus: the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 1998;93:1033-1036.
44. Sharma P, Weston AP, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut. 2000;46:9-13.
45. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310-330.
46. Shields HM, Zwas F, Antonioli DA, et al. Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett's epithelium. Dig Dis Sci. 1993;38:97-108.
47. Shields HM, Rosenberg SJ, Zwas FR, et al. Prospective evaluation of multilayered epithelium in Barrett's esophagus. Am J Gastroenterol. 2001;96:3268-3273.
48. Spechler SJ. The columnar-lined esophagus. History, terminology, and clinical issues. Gastroenterol Clin North Am. 1997;26:455-466.
49. van Baal JW, Milano F, Rygiel AM, et al. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology. 2005;129:1274-1281.
50. Wallner B, Sylvan A, Janunger KG, et al. Immunohistochemical markers for Barrett's esophagus and associations to esophageal Z-line appearance. Scand J Gastroenterol. 2001;36:910-915.
51. Weston AP, Krmpotich PT, Cherian R, et al. Prospective evaluation of intestinal metaplasia and dysplasia within the cardia of patients with Barrett's esophagus. Dig Dis Sci. 1997;42:597-602.
52. Wieczorek TJ, Wang HH, Antonioli DA, et al. Pathologic features of reflux and Helicobacter pylori-associated carditis: a comparative study. Am J Surg Pathol. 2003;27:960-968.
53. Younes M, Lechago J, Ertan A, et al. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus. Hum Pathol. 2000;31:434-438.